Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Positive|HER2/Neu Negative|Progesterone Receptor Positive|Stage IV Breast Cancer AJCC v6 and v7
Interventions: DRUG: Copanlisib|DRUG: Fulvestrant|OTHER: Laboratory Biomarker Analysis|DRUG: Palbociclib
Sponsor: National Cancer Institute (NCI)